头颈部肿瘤根治性治疗中大剂量立体定向放疗推量研究
25例(89%)达完全缓解,推量大小和时机不影响缓解;切缘阳性使转移风险增加18倍(p=0.015)、死亡风险增加3倍(p=0.030);生物有效剂量超过143.33 Gy后晚期毒性风险增加(p=0.0148)。
要点
- 推量剂量或时机与完全缓解无关;切缘阳性显著增加转移和死亡风险。
- 生物有效剂量超过143.33 Gy后晚期毒性风险增加,10 Gy推量耐受性可接受。
核心结论
- 10 Gy推量是耐受性可接受的 promising 治疗选择,更高剂量疗效相似但晚期毒性更大。
- 切缘阳性增加转移风险18倍(p=0.015)和死亡风险3倍(p=0.030)。
- 生物有效剂量超过143.33 Gy后晚期毒性风险增加(p=0.0148)。
研究设计与样本
- 立体定向推量于常规放疗前或后最多6天给予原发肿瘤或转移淋巴结,剂量8–18 Gy。
主要发现
- 25例(89%)观察到完全缓解,缓解不依赖推量大小或时机。
- 5例死于疾病进展。
- 较高Zubrod体能状态与更重的急性黏膜和皮肤毒性相关。
- 最严重晚期并发症为颈动脉破裂综合征(伴放线菌共感染)和脑坏死。
关键数值与推荐
- 推量剂量范围8–18 Gy。
- 完全缓解25例(89%)。
- 切缘阳性:转移风险增加18倍(p=0.015),死亡风险增加3倍(p=0.030)。
- 生物有效剂量超过143.33 Gy与晚期毒性风险增加相关(p=0.0148)。
临床怎么用
- 可考虑在常规分割放疗基础上联合10 Gy立体定向推量,耐受性可接受。
- 应关注切缘阳性患者,其转移和死亡风险显著增高。
- 推量生物有效剂量超过143.33 Gy时需警惕晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current results of head and neck cancer treatment remain suboptimal therefore, novel approaches are needed to improve its effectiveness. This prospective, single-center study aims to assess the results and safety of combining conventionally fractionated radiotherapy with a high-dose stereotactic radiotherapy boost in radical treatment. METHODS: Twenty-eight patients with head and neck tumors of diverse localizations and histopathologies were recruited. The stereotactic boost was delivered to primary tumors or metastatic nodes up to 6 days before or after conventional radiotherapy. The boost doses ranged from 8 to 18 Gy. RESULTS: A complete response was observed in 25 patients (89%). The response did not depend on boost size or its timing within the regimen. Disease progression caused death in 5 cases. Positive surgical margins increased the risk of metastasis eighteenfold (p = 0.015) and mortality threefold (p = 0.030). A higher Zubrod performance status correlated with greater acute mucosal and skin toxicity. The most severe late complications were carotid blow-out syndrome (with actinomycosis coinfection) and brain necrosis. The risk of late toxicity increased after exceeding a biological effective dose of 143.33 Gy (p = 0.0148). CONCLUSIONS: A boost with a dose of 10 Gy represents a promising treatment option with permissible tolerance, with higher doses offering similar efficacy but greater late toxicity. TRIAL REGISTRATION: The study protocol was approved by the local Bioethics Committee (KB/430 - 87/19) and registered on the ClinicalTrials.gov (NCT06472570) on 25 June 2024.
引用
- Polanowski P, Tukiendorf A, Nasiek A, et al. High-dose stereotactic radiotherapy boost in the radical treatment of head and neck tumors. Radiat Oncol. 2026. PMID: 42216211. doi:10.1186/s13014-026-02857-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。